Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy

2006 ◽  
Vol 29 (1-2) ◽  
pp. 39-43 ◽  
Author(s):  
Karin Jordan
Keyword(s):  
Antiemetic Therapy ◽  
Receptor Antagonists ◽  
New Approach ◽  
Neurokinin 1 Receptor ◽  
Neurokinin 1

scholarly journals Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review

2012 ◽  
Vol 104 (17) ◽  
pp. 1280-1292 ◽  
Author(s):  
L. V. dos Santos ◽  
F. H. Souza ◽  
A. T. Brunetto ◽  
A. D. Sasse ◽  
J. P. da Silveira Nogueira Lima
Keyword(s):  
Systematic Review ◽  
Nausea And Vomiting ◽  
Receptor Antagonists ◽  
Neurokinin 1 Receptor ◽  
Neurokinin 1

scholarly journals Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK 1/2 activation

2019 ◽  
Vol 33 (12) ◽  
pp. 2371-2379 ◽  
Author(s):  
K. Agelopoulos ◽  
F. Rülander ◽  
J. Dangelmaier ◽  
T. Lotts ◽  
N. Osada ◽  
...  
Keyword(s):  
Receptor Antagonists ◽  
Prurigo Nodularis ◽  
Neurokinin 1 Receptor ◽  
Neurokinin 1

State-wide quality improvement addressing overutilization of neurokinin-1 receptor antagonists.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 8-8
Author(s):  
Emily R. Mackler ◽  
Kelly Marie Procailo ◽  
Louise Bedard ◽  
Jennifer J. Griggs
Keyword(s):  
Quality Improvement ◽  
Response Rate ◽  
Quality Improvement Intervention ◽  
Receptor Antagonists ◽  
Post Intervention ◽  
Improvement Program ◽  
Neurokinin 1 Receptor ◽  
Order Sets ◽  
Neurokinin 1 ◽  
Order Set

8 Background: The overuse of neurokinin-1 receptor antagonists (NK1-RAs) is a focus of quality measurement within the American Society of Clinical Oncology Quality Oncology Practice Initiative (ASCO-QOPI) and the American Board of Internal Medicine (ABIM) as a Choosing Wisely measure. The Michigan Oncology Quality Collaborative (MOQC) is a statewide collaborative with participation of nearly 100% of oncologists. The purpose of this project was to provide quality improvement practice support for deimplementation of NK1-RAs in the upfront prevention of chemotherapy- induced nausea and vomiting (CINV) for low and moderate emetic chemotherapy regimens (QOPI measure SMT28a) to less than 30% in practices across the State, with lower scores indicating better performance. Methods: In 2018, MOQC added the QOPI SMT28a measure as part of its standard quality measure module for collection by all MOQC practices. A quality improvement intervention was initiated that consisted of 1) baseline assessments of measure performance, prescriber knowledge and beliefs, and pre-populated antiemetic order sets, 2) reporting practice and state-level performance to MOQC practices, 3) state-wide CINV education, and 4) a value-based reimbursement (VBR) related to measure performance. Post-intervention performance was assessed with the Fall 2019 and Spring 2020 QOPI-measurement. Results: Responses from a survey assessing pre-populated antiemetic order sets (32/43, 74% response rate), 23% of practices had a pre-populated order set for NK1-RA and/or olanzapine in moderate emetic regimens. The post-education order set survey found that 48% of respondents (25/43, 54% response rate) either modified or were in the process of modifying their order sets. Conclusions: Deimplementation of unnecessary and low value antiemetics in patients receiving low- or moderate emetic chemotherapy was possible via a state-wide quality improvement program that involved performance reporting to practices, collaborative-wide education, modification of standing order sets, and VBR based on performance. [Table: see text]

Potent, Brain-Penetrant, Hydroisoindoline-Based Human Neurokinin-1 Receptor Antagonists

2009 ◽  
Vol 52 (9) ◽  
pp. 3039-3046 ◽  
Author(s):  
Jinlong Jiang ◽  
Jaime L. Bunda ◽  
Geoge A. Doss ◽  
Gary G. Chicchi ◽  
Marc M. Kurtz ◽  
...  
Keyword(s):  
Receptor Antagonists ◽  
Neurokinin 1 Receptor ◽  
Neurokinin 1
Sign in / Sign up

Export Citation Format

Share Document